Asymchem Laboratories (Tianjin) Co., Ltd.
002821
Classement en actions
#2511
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development... Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
Prix de l'action
$20.91
Capitalisation boursière
$7.57B
Changement (1 jour)
-8.26%
Changement (1 an)
41.25%
Pays
CN
Échange Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Catégorie
Healthcare
Bénéfices pour Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Bénéfices en Jun 2026 TTM : $175.62M
Selon les derniers rapports financiers de Asymchem Laboratories (Tianjin) Co., Ltd., les bénéfices actuels de l'entreprise sont de $175.62M. En 2024, l'entreprise a réalisé un bénéfice de $146.92M, une diminution par rapport à celui de 2023 qui était de $361.25M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Asymchem Laboratories (Tianjin) Co., Ltd. de 2011 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $175.62M | -4.48% |
| 2025 | $183.86M | 25.15% |
| 2024 | $146.92M | -59.33% |
| 2023 | $361.25M | -33.10% |
| 2022 | $540.01M | 187.71% |
| 2021 | $187.69M | 51.14% |
| 2020 | $124.18M | 38.67% |
| 2019 | $89.55M | 33.73% |
| 2018 | $66.96M | 3.22% |
| 2017 | $64.87M | 38.39% |
| 2016 | $46.88M | 52.55% |
| 2015 | $30.73M | 43.65% |
| 2014 | $21.39M | 28.73% |
| 2013 | $16.62M | 23.63% |
| 2012 | $13.44M | -5.39% |
| 2011 | $14.21M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 2,903.53% |
US
|
|
| $-3.09B | -1,857.74% |
US
|
|
| $-4.02B | -2,386.83% |
AU
|
|
| $2.85B | 1,520.36% |
BE
|
|
| $1.95B | 1,010.70% |
NL
|
